Outcome of Board Meeting

Date: November 03, 2026 BSE Limited, National Stock Exchange of India Limited 20th Floor, P.J. Towers, Exchange Plaza, C-1, Block G, Dalal Street, Bandra Kurla Complex, Bandra (E), Mumbai - 400001. Mumbai – 400 051 BSE Scrip Code: 544449 NSE Scrip Symbol: ANTHEM Subject: Outcome of the Board Meeting held on Tuesday, November 03, 2026 Dear Sir/Ma’am Pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI LODR”), we would like to inform you that the Board of Directors of Anthem Biosciences Limited (formerly known as Anthem Biosciences Private Limited) ("Company") at their meeting held on Tuesday, November 03, 2026 which commenced at 2.30 p.m. and concluded at 03:45 p.m. have inter-alia, approved the Unaudited Standalone and Consolidated Financial Results along with Limited Review Report of Statutory Auditors for the quarter and half year ended September 30, 2026. The said financials results were duly reviewed and recommended by Audit Committee at its meeting held on same day to the Board. A copy of the said Unaudited Standalone and Consolidated Financial Results along with Limited Review Report of the Statutory Auditors are enclosed herewith and the extract of the results will be published in the newspapers as required under Regulation 47(1) of SEBI LODR Regulations. The above intimation is also available on the Company’s website at https://anthembio.com/investors/. We request you to kindly take the same on record. Thanking you, Yours truly, For Anthem Biosciences Limited (Formerly known as Anthem Biosciences Private Limited) Divya Prasad Company Secretary & Compliance Officer Membership No: A41438 S.R. BATLIBOI & ASSOCIATES LLP [y — Chartered Accountants No. 24, Vittal Mallya Road Bengaluru - 560 001, India Tel : 491 80 6648 9000 Independent Auditor’s Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended Review Report to The Board of Directors Anthem Biosciences Limited (formerly known as Anthem Biosciences Private Limited) 1 We have reviewed the accompanying statement of unaudited standalone financial results of Anthem Biosciences Limited (formerly known as Anthem Biosciences Private Limited) (the “Company”) for the quarter ended September 30, 2026 and year to date from April 01, 2026 to September 30, 2026 (the “Statement”) attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the “Listing Regulations”). The Company’s Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) “Interim Financial Reporting” prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company’s Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, “Review of Interim Financial Information Performed by the Independent Auditor of the Entity” issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards (‘'Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement. S.R. BATLIBOI & ASSOCIATES LLP Chartered Accountants 5. The comparative financial information of the Company for the quarter ended June 30, 2026, quarter and period ended September 30, 2025, included in these standalone financial results were reviewed by the predecessor auditor and the financial statements of the Company for the year ended March 31,2026, were audited by predecessor auditor who expressed an unmodified conclusion and unmodified opinion on those financial information on July 21, 2026, November 08, 2025 and May 19, 2026 respectively. For S.R. Batliboi & Associates LLP Chartered Accountants ICAI Firm registration number: 101049W /E300004 per Rajeev Partner Membership No.: 213803 Unique Document Identification Number: 26 23803 WFZ-X RS 650 Place: Bengaluru Date: November 03, 2026 ANTHEM BIOSCIENCES LIMITED (FORMERLY KNOWN AS ANTHEM BIOSCIENCES PRIVATE LIMITED) Corporate 1dentity Number: L24233KA2006PLC039703 Registered and Corporate Office: No 49, ) and F2, Canara Bank Road, Bommasandra Industrial Area, Phase-], Bommasandra, Bangalore-560099 Karnataka India Email ; investors.abl@anthembio.com Telephone: +91 080 6672 4000 Website: www.anthembio.com Statement of Unaudited Standalone Financial Resulls for the Quarter and Half year ended Septembe3r0, 2026 (2. in Million) Particulars Quarter ended Half year ended Year ended 30.09.2026 | 30.06.2026 | 30.09.2025 | 30.09.2026 | 30.09.2025 31.03.2026 Unaudited | Unaudited | Unaudited | Unaudited | Unaudited Audited Income Revenue from operations 5,721.08 3,838.42 5,527.03 9,559.50 10,913.71 20,942.99 Other income 646.95 286.00 533.22 932.95 803.93 1,770.88 | Total income 6,368.03 4,124.42 6,060.25 1049245 11,717.64 22,713.87 Expenses Cost of materials consumed 1,934.43 1,449.45 2,037.12 3,383.88 3,661.07 6,967.51 Changes in inventories of finished goods and work-in-progress (109.53) (3.64) 2098 (13317) 90770 986,91 [Employee benefits expense 743.02 727.79 626.33 1,470.81 1,310.41 2,624.63 Finance costs 30.63 763 2256 38.26 39.15 67.08 Depreciation and amortisation expense 22214 223.10 239.20 44524 465.33 995.65 Other expense 506.17 376.49 381.04 882.66 811.58 1,801.25 [ Total expense 3,326.86 2,760.82 3,527.23 6,087.68 7,195.24 13,443.03 Profit before exceptional items and tax 3,041.17 1,363.60 2,533.02 4,404.77 4,522.40 9,270.84 Fxceptional items - = = = : 240.14 Profit before tax 3,041.17 1,363.60 2,533.02 4,404.77 4,522.40 9,030.70 Tax expense | Current tax 81197 347.06 637.51 1,159.03 1,138.20 2,413.05 Adjustment of tax relating to earlier periods 4010 = = 010 2 = Deferred tax credit (19.76) (355 (883) (2331) (8353) 87.99) |T otal tax expense 832,31 34351 548.68 1,175.82 1,054.67 2,325.06 Profit for the period/year 2,208.86 1,020.09 1,984.34 3,228.95 3,467.73 6,705.64 (Other comprehensive income/(loss) Items that will not be reclassified subsequently o profit or loss Remeasurement (loss)/gain on defined employee benefit plans (56.51) 937 (1939 (4714 069 (20.09) Income tax ct on above 14.23 (2.36) 4.88 11.87 (0.17) 5.04] (@2.28) 7.01 @@sl) (3527 052 (15.00) Items [Showing first 8,000 characters — download PDF for full document]